Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly & Co ( (LLY) ) has provided an update.
At Eli Lilly & Co.’s annual meeting of shareholders held on May 4, 2026, investors representing about 90% of outstanding shares cast votes on board elections, executive pay, auditor ratification, and several governance-related proposals. Shareholders elected four directors, including CEO David Ricks, to three-year terms ending in 2029 and gave advisory approval to the company’s executive compensation program, while also ratifying Ernst & Young as independent auditor for 2026.
However, key governance reforms failed to reach the required 80% threshold of outstanding shares, leaving Eli Lilly’s classified board structure and supermajority voting provisions in place despite majority support. Shareholders also rejected proposals to require an independent board chair and to mandate an annual lobbying report, signaling continued backing for the existing leadership and governance framework, but limiting changes sought by some investor groups.
The most recent analyst rating on (LLY) stock is a Buy with a $1285.00 price target. To see the full list of analyst forecasts on Eli Lilly & Co stock, see the LLY Stock Forecast page.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
The score is driven primarily by outstanding financial performance and a strongly positive earnings call with raised guidance. Offsetting factors are a premium valuation and mixed/neutral technical signals, with leverage and pricing pressure remaining key risks to monitor.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
Eli Lilly & Co. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines, with a portfolio focused on areas such as diabetes, oncology, immunology, and neuroscience. The company targets both U.S. and international healthcare markets, supplying innovative therapies to patients, hospitals, and healthcare systems worldwide.
Average Trading Volume: 3,092,283
Technical Sentiment Signal: Strong Buy
Current Market Cap: $929.5B
Find detailed analytics on LLY stock on TipRanks’ Stock Analysis page.